First ‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
ConclusionIn a real ‐life cohort of advanced NSCLC patients (including PS 2 and untreated brain metastases), with PD‐L1 TPS ≥50%, pembrolizumab demonstrates similar PFS to the pivotal clinical trial.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Karim Amrane,
Margaux Geier,
Romain Corre,
Herv é Léna,
Guillaume Léveiller,
Florence Gadby,
Régine Lamy,
Jean‐Louis Bizec,
Eric Goarant,
Gilles Robinet,
Sylvie Gouva,
Gilles Quere,
Ronan Abgral,
Ulrike Schick,
Cyril Bernier,
Christos Tags: ORIGINAL RESEARCH Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | France Health | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Smokers | Study